Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 9/20 | 0.33 |
| ▸ | CES1 | P23141 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7029253 | 1.00 | CES2 (0.37) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL1769903 | 0.94 | CES2 (0.32) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL848224 | 0.83 | — | — | |
| SCHEMBL2680481 | 0.83 | — | — | |
| SCHEMBL8520645 | 0.83 | — | — | |
| SCHEMBL1581509 | 0.82 | — | — | |
| SCHEMBL1581276 | 0.82 | — | — | |
| SCHEMBL1581563 | 0.82 | — | — | |
| SCHEMBL14861335 | 0.82 | — | — | |
| SCHEMBL1581124 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280929-A2 | VECTORS FOR OCULAR TRANSDUCTION AND USE THEREOF FOR GENETIC THERAPY | Novartis AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001083729-A2 | VECTORS FOR OCULAR TRANSDUCTION AND USE THEREOF FOR GENETIC THERAPY | NOVARTIS AG (CH) | 2001-11-08 | — | — | WO | disclosed |
| EP-1082142-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF GENETIC MATERIAL FOR ALTERING NEURONAL GROWTH, REGENERATION, AND SURVIVAL | Selective Genetics, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999066959-A9 | COMPOSITIONS AND METHODS FOR DELIVERY OF GENETIC MATERIAL FOR ALTERING NEURONAL GROWTH, REGENERATION, AND SURVIVAL | SELECTIVE GENETICS INC (US) | 2000-03-30 | — | — | WO | disclosed |
| EP-0973926-A1 | ADENOVIRAL VECTORS WITH MODIFIED TROPISM | Selective Genetics, Inc. (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1999066959-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF GENETIC MATERIAL FOR ALTERING NEURONAL GROWTH, REGENERATION, AND SURVIVAL | SELECTIVE GENETICS, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1998040508-A1 | ADENOVIRAL VECTORS WITH MODIFIED TROPISM | SELECTIVE GENETICS, INC. (US) | 1998-09-17 | — | — | WO | disclosed |
| WO-1998039436-A2 | FIBROBLAST GROWTH FACTOR MUTEIN COMPOSITIONS AND METHODS OF USE THEREFOR | EISAI CO., LTD. (JP) | 1998-09-11 | — | — | WO | disclosed |
| EP-0833665-A1 | COMPOSITIONS CONTAINING NUCLEIC ACIDS AND LIGANDS FOR THERAPEUTIC TREATMENT | PRIZM PHARMACEUTICALS, INC. (US) | 1998-04-08 | — | — | EP | disclosed |
| EP-0776218-A2 | HEPARIN-BINDING GROWTH FACTORS FOR GENE THERAPY AND ANTERIOR EYE DISORDERS | PRIZM PHARMACEUTICALS, INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| EP-0754046-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN, William R. (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1996036362-A1 | COMPOSITIONS CONTAINING NUCLEIC ACIDS AND LIGANDS FOR THERAPEUTIC TREATMENT | PRIZM PHARMACEUTICALS, INC. (US) | 1996-11-21 | — | — | WO | disclosed |
| WO-1995026734-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN WILLIAM R (US) | 1995-10-12 | — | — | WO | disclosed |
| WO-1995024928-A2 | HEPARIN-BINDING GROWTH FACTORS FOR GENE THERAPY AND ANTERIOR EYE DISORDERS | PRIZM PHARMACEUTICALS, INC. (US) | 1995-09-21 | — | — | WO | disclosed |